Next Article in Journal
Detection of up to 65% of Precancerous Lesions of the Human Colon and Rectum by Mutation Analysis of APC, K-Ras, B-Raf and CTNNB1
Next Article in Special Issue
Membrane Drug Transporters and Chemoresistance in Human Pancreatic Carcinoma
Previous Article in Journal
Doxorubicin-Loaded PEG-PCL-PEG Micelle Using Xenograft Model of Nude Mice: Effect of Multiple Administration of Micelle on the Suppression of Human Breast Cancer
Previous Article in Special Issue
Pain Management in Pancreatic Cancer
Article Menu

Export Article

Open AccessReview
Cancers 2011, 3(1), 79-90;

Screening Technologies for Target Identification in Pancreatic Cancer

Department of Gastroenterology and Endocrinology, University Hospital, Philipps-University Marburg, Baldinger Strasse, D-35043 Marburg, Germany
Author to whom correspondence should be addressed.
Received: 23 November 2010 / Revised: 21 December 2010 / Accepted: 23 December 2010 / Published: 29 December 2010
(This article belongs to the Special Issue Pancreatic Cancer)
Full-Text   |   PDF [306 KB, uploaded 29 December 2010]   |  


Pancreatic cancer exhibits an extraordinarily high level of resistance to almost any kind of systemic therapy evaluated in clinical trials so far. Therefore, the identification of novel therapeutic targets is urgently required. High-throughput screens have emerged as an important tool to identify putative targets for diagnosis and therapy in an unbiased manner. More than a decade ago, microarray technology was introduced to identify differentially expressed genes in pancreatic cancer as compared to normal pancreas, chronic pancreatitis and other cancer types located in close proximity to the pancreas. In addition, proteomic screens have facilitated the identification of differentially secreted proteins in body fluids of pancreatic cancer patients, serving as possible biomarkers. Recently, RNA interference-based loss-of-function screens have been used to identify functionally relevant genes, whose knock-down has impact on pancreatic cancer cell viability, thereby representing potential new targets for therapeutic intervention. This review summarizes recent results of transcriptional, proteomic and functional screens in pancreatic cancer and discusses potentials and limitations of the respective technologies as well as their impact on future therapeutic developments. View Full-Text
Keywords: pancreatic cancer; high-throughput screen; microarray; RNA interference; loss-of-function screen pancreatic cancer; high-throughput screen; microarray; RNA interference; loss-of-function screen

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Michl, P.; Ripka, S.; Gress, T.; Buchholz, M. Screening Technologies for Target Identification in Pancreatic Cancer. Cancers 2011, 3, 79-90.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top